Sign In
Buy TEVA
$32.83
-0.250 (-0.756%)
At Close: Jun 03, 2026
Teva Pharmaceutical Industries Ltd (TEVA) Stock Down 4.5% but Still Overvalued -- GF Score: 55/100
06:27pm, Tuesday, 02'nd Jun 2026
On June 02, 2026, Teva Pharmaceutical Industries Ltd (TEVA) shares fell 4.5% to a current price of $33.08. This decline comes in the context of a 52-week tradin
Teva to Present at the Goldman Sachs Global Healthcare Conference
04:30pm, Monday, 01'st Jun 2026
PARSIPPANY, N.J., and TEL AVIV, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will
Teva Pharmaceutical Industries Just Pulled Off One of Pharma's Most Impressive Comebacks
12:15am, Monday, 01'st Jun 2026
Thanks to its pivot from generic to branded drug products, Teva Pharmaceutical Industries has experienced a dramatic price rebound. Even after surging 90% higher over the past year, Teva's comeback ma
TEVA's Growth Story Is No Longer Just Generic, It's Getting Branded
03:15am, Monday, 25'th May 2026
Teva Pharmaceutical (TEVA) delivered a strong Q1 2026, reinforcing my buy rating and the company's successful pivot to innovative growth assets. TEVA's innovative neuroscience franchise—AUSTEDO, AJO
TEVA's MAA for Olanzapine LAI in Schizophrenia Accepted in the EU
12:40pm, Friday, 22'nd May 2026
Teva aims to expand its schizophrenia portfolio after the EMA accepts its filing for olanzapine long-acting injectable (TEV-'749).
TEL AVIV, Israel and PARIS, May 21, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) and Medincell (Euronext
Teva Stock Up More Than 100% in a Year: Time to Buy, Hold or Sell?
12:26pm, Tuesday, 19'th May 2026
Teva's branded drug growth, biosimilar launches and improving margins are strengthening its long-term outlook despite generics pressure.
Fitch Upgrades Teva to Investment Grade Amid Pivot to Growth Execution
08:30am, Monday, 18'th May 2026
TEL AVIV, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Fitch Ratings Agency (“Fitch”) has raised the Company's corporate
PARSIPPANY, N.J. and TEL AVIV, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data fr
Larry Robbins' Strategic Moves: Significant Reduction in Teva Pharmaceutical Industries Ltd
11:09pm, Friday, 15'th May 2026
Insights into Glenview Capital Management's First Quarter 2026 Portfolio Adjustments Larry Robbins (Trades, Portfolio) recently submitted the 13F filing for th
Teva Stock Is at Its Highest Level in Nearly a Decade. Here's Why It Could Soar Even More.
01:00am, Friday, 15'th May 2026
Teva is pivoting from generic-drug maker to major pharmaceutical company. Even after more than doubling in price over the past year, shares have more room to run, thanks to the company's robust pipeli
Wall Street Thinks Teva Stock Still Has Room to Run After Soaring Over 100%. Here's Why Analysts Are Right.
04:56am, Thursday, 14'th May 2026
Teva's turnaround is real -- and may not be over.
Teva Pharmaceutical Industries Limited (TEVA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
03:30pm, Tuesday, 12'th May 2026
Teva Pharmaceutical Industries Limited (TEVA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Teva to Present at the BofA Securities Health Care Conference
04:30pm, Monday, 04'th May 2026
PARSIPPANY, N.J., and TEL AVIV, Israel, May 04, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Eric Hughes, Teva's EVP of Global R&D & Chief Me
TEVA Q1 Earnings Top Estimates, Branded Drugs Drive Revenues, Stock Up
11:20am, Thursday, 30'th Apr 2026
Teva beats Q1 earnings and revenue estimates as Austedo, Ajovy and Uzedy fuel growth, lifting shares despite weaker generics performance.
